Article
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
The Lancet. Infectious diseases - 1 Apr 2023
Domínguez José, Boeree Martin J, Cambau Emmanuelle, Chesov Dumitru, Conradie Francesca, Cox Vivian, Dheda Keertan, Dudnyk Andrii, Farhat Maha R, Gagneux Sebastien, Grobusch Martin P, Gröschel Matthias I, Guglielmetti Lorenzo, Kontsevaya Irina, Lange Berit, van Leth Frank, Lienhardt Christian, Mandalakas Anna M, Maurer Florian P, Merker Matthias, Miotto Paolo, Molina-Moya Barbara, Morel Florence, Niemann Stefan, Veziris Nicolas, Whitelaw Andrew, Horsburgh Charles R, Lange Christoph
Abstract excerpt
Drug-resistant tuberculosis is a substantial health-care concern worldwide. Despite culture-based methods being considered the gold standard for drug susceptibility testing, molecular methods provide rapid information about the Mycobacterium tuberculosis mutations associated with resistance to anti-tuberculosis drugs. This consensus document was developed on the basis of a comprehensive literature search, by the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.